Tag: Viaskin® Peanut

Moonlight Therapeutics Microneedle Patch

New Microneedle Patch Therapy for Food Allergies Takes Step Forward

Painless microneedle patch may provide new method for desensitization.
Viaskin Patch

DBV Optimistic Viaskin Peanut “Patch” Therapy has Path to Approval After...

DBV, which also has Viaskin therapies for milk and egg allergies in their pipeline, is encouraged by FDA feedback after denial of their peanut therapy.
DBV Patch Closeup

DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...

The company announced they would be laying off 200 employees in Q1.
Viaskin Patch

Viaskin Peanut “Patch” Therapy Takes Next Step Toward Approval… in Europe

The Marketing Authorization Application for Viaskin™ Peanut was validated by the European Medicines Agency.
Viaskin Peanut

FDA Denies Approval of Viaskin Peanut “Patch” Therapy

The FDA raised concerns that adhesion of the patch would affect the efficacy of the therapy.
Viaskin Patch

Will the Viaskin “Patch” Therapy for Peanut Allergy be Approved Soon?...

Company is restructuring in anticipation of delays.
Viaskin-Patch-Delay

FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV...

The company warned the FDA's target date for their decision on approval could be delayed.
Viaskin-Patch

FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...

Next step in the approval process for the therapy scheduled for May 15, 2020.
Viaskin Peanut

DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...

Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
Viaskin Peanut

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...

If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.